Nucleic acid sequencing processes using non-radioactive detectable modified or labeled nucleotides or nucleotide analogs, and other processes for nucleic acid detection and chromosomal characterization using such non-radioactive detectable modified or labeled nucleotides or nucleotide analogs

DC CAFC

US 8,097,405 B1
Filed: 06/07/1995
Issued: 01/17/2012
Est. Priority Date: 06/23/1982
Status: Active Grant

- Alert
- Pin

Associated Cases

Associated Defendants

First Claim

Patent Images

1. A process for detecting a nucleic acid of interest in a sample, which process comprises:

(A) providing a sample which may contain a nucleic acid of interest;

(B) providing;

(i) an oligo- or polynucleotide that comprises two segments, the first segment comprising a nucleotide sequence that is complementary to and capable of specifically hybridizing to and forming a hybrid with said nucleic acid of interest or a portion thereof, and the second segment comprising an operator sequence that is capable of binding to or complexing with a non-radioactively detectable protein; and

(ii) a non-radioactively detectable protein which is non-radioactive and has a binding affinity to said operator sequence;

(C) contacting a sample suspected of containing said nucleic acid of interest with said oligo- or polynucleotide (i) and said non-radioactively detectable protein (ii) to form a complex; and

(D) detecting non-radioactively the presence of said non-radioactively detectable protein in said complex to detect said nucleic acid of interest.

View all claims

1 Assignment

Timeline View

Assignment View

Litigations

0 Petitions

Accused Products

Abstract

A process for determining the sequence of nucleic acids of interest employs nucleotides or nucleotide analogs that have been made detectable by non-radioactive modifying or labeling. Such nucleotides or nucleotide analogs are modified on the sugar moieties, the phosphate moieties or the base moieties, including base analogs. Modified nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA. The modified or labeled nucleotides or nucleotide analogs are also useful in processes for detecting the presence of nucleic acids of interest and for characterizing chromosomal sequences. Detection processes using the modified or labeled nucleotides or nucleotide analogs extend to the use of a gel for separating or resolving hybrids formed between non-radioactively labeled oligonucleotides or polynucleotides and such nucleic acids of interest.

75 Citations

View as Search Results

198 Claims

1. A process for detecting a nucleic acid of interest in a sample, which process comprises:
- (A) providing a sample which may contain a nucleic acid of interest;
  
  (B) providing;
  
  (i) an oligo- or polynucleotide that comprises two segments, the first segment comprising a nucleotide sequence that is complementary to and capable of specifically hybridizing to and forming a hybrid with said nucleic acid of interest or a portion thereof, and the second segment comprising an operator sequence that is capable of binding to or complexing with a non-radioactively detectable protein; and
  
  (ii) a non-radioactively detectable protein which is non-radioactive and has a binding affinity to said operator sequence;
  
  (C) contacting a sample suspected of containing said nucleic acid of interest with said oligo- or polynucleotide (i) and said non-radioactively detectable protein (ii) to form a complex; and
  
  (D) detecting non-radioactively the presence of said non-radioactively detectable protein in said complex to detect said nucleic acid of interest.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62)
- - 2. The process according to claim 1, wherein the nucleic acid of interest comprises DNA, RNA or a DNA-RNA hybrid.
  - 3. The process according to claim 1, wherein the nucleic acid of interest is double-stranded or single-stranded.
  - 4. The process according to claim 1, wherein the nucleic acid of interest has been rendered single-stranded.
  - 5. The process according to claim 1, wherein the nucleic acid of interest is derived from an organism.
  - 6. The process according to claim 5, wherein the organism comprises prokaryotes or eukaryotes.
  - 7. The process according to claim 5, wherein said organism bacteria, fungi, viruses, yeast or mammals.
  - 8. The process according to claim 5, wherein said organism is living.
  - 9. The process according to claim 1, wherein the sample is suspected of containing an etiological agent and the nucleic acid of interest is naturally associated with the etiological agent.
  - 10. The process according to claim 9, wherein the sample is of human or animal origin and the etiological agent comprises bacteria, virus or fungi.
  - 11. The process according to claim 1, wherein said nucleic acid of interest is derived from an organism comprising Streptococcus pyrogenes, Neisseria meningitides, Staphylococcus aureus, Candida albicans, Pseudomonas aeruginosa, Neisseria gonorrhoeae, or Mycobacterium tuberculosis.
  - 12. The process according to claim 1, wherein said one or more oligo- or polynucleotides are derived from Neisseria gonorrhoeae sequences.
  - 13. The process according to claim 1, wherein the sample comprises a bacterium suspected of containing a nucleic acid of interest which imparts resistance to an antibiotic and wherein the oligo- or polynucleotide comprises a polynucleotide complementary to the sequence of the bacterium which confers resistance to the antibiotic.
  - 14. The process according to claim 13, wherein when said bacterium is Streptococcus pyrogenes or Neisseria meningtidis, said antibiotic is penicillin, wherein when said bacterium is Staphylococcus aureus, Candida albicans, Pseudomonas aeruginosa, Streptococcus pyrogenes, or Neisseria gonorrhoea, said antibiotic is a tetracycline, and wherein when said bacterium is Mycobacterium tuberculosis, said antibiotic is an aminoglycoside.
  - 15. The process according to claim 14, wherein said bacterium is Neisseria gonorrhoeae and said antibiotic comprises penicillin, tetracycline, aminoglycoside or combinations thereof.
  - 16. The process according to claim 1, wherein the sample is suspected of containing a nucleic acid of interest associated with a genetic disorder and wherein the oligo- or polynucleotide comprises a polynucleotide complementary to the nucleic acid associated with the genetic disorder.
  - 17. The process according to claim 1, wherein said sample is suspected of containing a nucleic acid of interest associated with thalassemia and wherein the oligo- or polynucleotide comprises a polynucleotide complementary to the nucleic acid which is absent in the thalassemic subjects.
  - 18. The process according to claim 1, wherein said process is utilized for chromosomal karyotyping which comprises contacting the sample with a series of the oligo- or polynucleotides (i) which are complementary to a series of known genetic sequences located on chromosomes.
  - 19. The process according to claim 1, wherein said process is utilized to determine the number of copies of an individual chromosome in a sample.
  - 20. The process according to claim 1, wherein said non-radioactive detectable protein comprises an antibody, a promoter, a repressor or an inducer.
  - 21. The process according to claim 20, wherein said repressor comprises a lac repressor.
  - 22. The process according to claim 20, wherein said operator sequence is covalently attached to said oligo- or polynucleotide.
  - 23. The process according to claim 22, wherein said covalent attachment has been carried out by ligation.
  - 24. The process according to claim 22, wherein said covalent attachment does not interfere substantially with the characteristic ability of said non-radioactively detectable protein to bind to any hybrid formed between said oligo- or polynucleotide and said nucleic acid of interest.
  - 25. The process according to claim 22, wherein said covalent attachment does not interfere substantially with the characteristic ability of said non-radioactively detectable protein to be detected non-radioactively when bound to any hybrid formed between said oligo- or polynucleotide and said nucleic acid of interest.
  - 26. The process according to claim 22, wherein said operator sequence is attached via a covalent attachment by an olefinic bond at the α
    - -position relative to the point of attachment to said nucleotide structure or nucleotide analog structure (i), a CH₂NH—
      
      moiety, or both.
  - 27. The process according to claim 26, wherein said covalent attachment comprises an allylamine group.
  - 28. The process according to claim 26, wherein said covalent attachment comprises or includes an olefinic bond at the α
    - -position relative to the point of attachment to the nucleotide, or any of the moieties
  - 29. The process according to claim 22, wherein said covalent attachment comprises a glycosidic linkage moiety.
  - 30. The process according to claim 22, wherein said operator sequence is covalently attached to any of the base, phosphate, or furanosyl moieties in said oligo- or polynucleotide.
  - 31. The process according to claim 30, wherein said covalent attachment is through a linkage group.
  - 32. The process according to claim 31, wherein said linkage group comprises an amine.
  - 33. The process according to claim 32, wherein said amine comprises a primary amine.
  - 34. The process according to claim 31, wherein said linkage group does not substantially interfere with the binding of said non-radioactively detectable protein to said operator sequence.
  - 35. The process according to claim 1, wherein said non-radioactively detectable protein comprises a signalling component or indicator molecule.
  - 36. The process according to claim 35, wherein said signalling component or indicator molecule comprises at least three carbon atoms.
  - 37. The process according to claim 36, wherein said signalling component or indicator molecule comprises an aliphatic chemical moiety comprising at least three carbon atoms and at least one double bond.
  - 38. The process according to claim 36, wherein said signalling component or indicator molecule comprises an aliphatic chemical moiety comprising at least four carbon atoms.
  - 39. The process according to claim 36, wherein said signalling component or indicator molecule comprises an aromatic or cycloaliphatic group comprising at least five carbon atoms.
  - 40. The process according to claim 39, wherein said aromatic or cycloaliphatic moiety is fluorescent or chemiluminescent.
  - 41. The process according to claim 36, wherein said signalling component or indicator molecule comprises an aromatic or cycloaliphatic group comprising at least six carbon atoms.
  - 42. The process according to claim 41, wherein said aromatic or cycloaliphatic moiety is fluorescent or chemiluminescent.
  - 43. The process according to claim 36, wherein said signalling component or indicator molecule comprises a monosaccharide, polysaccharide or an oligosaccharide.
  - 44. The process according to claim 35, wherein said signalling component or indicator molecule comprises biotin, iminobiotin, an electron dense component, a magnetic component, an enzyme, a hormone component, a metal-containing component, a fluorescent component, a chemiluminescent component, an antigen, a hapten, an antibody component a chelating component, or any combination of any of the foregoing.
  - 45. The process according to claim 44, wherein said signalling component or indicator molecule comprises a chemiluminescent component.
  - 46. The process according to claim 44, wherein said signalling component or indicator molecule comprises a chelating component.
  - 47. The process according to claim 35, wherein said signalling component or indicator molecule comprises an aromatic structure.
  - 48. The process according to claim 47, wherein said aromatic structure is heterocyclic.
  - 49. The process according to claim 36, wherein said heterocyclic aromatic structure is fluorescent.
  - 50. The process according to claim 49, wherein said fluorescent heterocyclic aromatic structure comprises fluorescein, rhodamine, dansyl or any combination of any of the foregoing.
  - 51. The process according to claim 50, wherein said fluorescent heterocyclic aromatic structure comprises fluorescein.
  - 52. The process according to claim 1, wherein said non-radioactively detectable protein is detectable by a fluorescent measurement, a chemiluminescent measurement, or a combination thereof.
  - 53. The process according to claim 1, wherein said non-radioactively detectable protein is detectable when the oligo- or polynucleotide is contained in a double-stranded ribonucleic or deoxyribonucleic acid duplex formed with said nucleic acid of interest.
  - 54. The process according to claim 1, wherein said nonradioactively detectable protein is detectable when it is attached to said oligo- or polynucleotide directly or through a linkage group.
  - 55. The process according to claim 1, wherein said oligo- or polynucleotide is contacted with said sample suspected of containing the nucleic acid of interest prior to forming a complex with said non-radioactively detectable protein.
  - 56. The process according to claim 1, wherein said detecting step is carried out directly.
  - 57. The process according to claim 56, wherein said direct detection of the non-radioactively detectable protein is carried out on one or more signalling components or indicator molecules.
  - 58. The process according to claim 57, wherein said direct detection step is carried out by a fluorogenic structure, a chemiluminescent structure, an enzyme, or an electron dense structure.
  - 59. The process according to claim 1, wherein said detecting step is carried out indirectly.
  - 60. The process according to claim 59, wherein said indirect detection is carried out by a means comprising an antibody, an antigen, a hapten, a receptor, a ligand, an enzyme, a structure capable of binding to an insoluble phase, or a combination of any of the foregoing.
  - 61. The process according to claim 1, wherein said nonradioactively detectable protein is capable of being detected by means comprising an enzymatic measurement, a fluorescent measurement, a chemiluminescent measurement, a microscopic measurement or an electron density measurement.
  - 62. The process according to claim 1, further comprising one or more washing steps.

63. A process for determining whether the number of copies of a particular chromosome in a cell is normal or abnormal, the process comprising:
- providing at least one cell;
  
  contacting said cell under hybridizing conditions with one or more clones or DNA fragments, or oligo- or polynucleotides derived from said clone or clones, wherein said clones or fragments or oligo- or polynucleotides are capable of hybridizing specifically to a locus or loci of said particular chromosome or a portion thereof, wherein said clones or fragments or oligo- or polynucleotides comprise one or more detectable non-radioactive modified or labeled nucleotides or one or more detectable non-radioactively modified or labeled nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and wherein said modified or labeled nucleotides or modified or labeled nucleotide analogs comprise;
  
  (i) a nucleotide structure or nucleotide analog structure having the formula
  PM-SM-BASE-SigwhereinPM is a phosphate moiety,SM is a furanosyl moiety,BASE is a pyrimidine, a purine, or a 7-deazapurine base moiety; and
  
  Sig is a detectable non-radioactive moiety,wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE at a position other than the C5 position when BASE is a pyrimidine moiety, at a position other than the C8 position when BASE is a purine moiety, and at a position other than the C7 position when BASE is a 7-deazapurine moiety;
  
  (ii) a nucleotide structure or nucleotide analog structure having the formula
- View Dependent Claims (73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 181)
- - 73. The process according to any of claim 63, 64, 65 or 67, wherein said nucleotide analog has been attached terminally to DNA or RNA by means of an enzyme.
  - 74. The process according to claim 73, wherein said enzyme comprises terminal transferase.
  - 75. The process according to any of claim 63, 64, 65 or 67, wherein said nucleotide analog has been coupled to DNA or RNA by a coupling means comprising chemical coupling or enzymatic coupling.
  - 76. The process according to claim 75, wherein said chemical coupling has been carried out by a chemical coupling means comprising carbodiimide or formaldehyde.
  - 77. The process according to claim 75, wherein said enzymatic coupling has been carried out by an enzymatic coupling means comprising DNA ligase or RNA ligase.
  - 78. The process according to any of claim 63, 64, 65 or 67, wherein said incorporation comprises nick translation.
  - 79. The process according to any of claim 63, 64, 65 or 67, wherein said incorporation is carried out by means of a polymerizing enzyme.
  - 80. The process according to claim 79, wherein said polymerizing enzyme comprises a polymerase.
  - 81. The process according to claim 80, wherein said polymerase comprises DNA polymerase or RNA polymerase.
  - 82. The process according to any of claim 63, 64, 65 or 67, wherein PM comprises a mono-phosphate, a di-phosphate, a tri-phosphate or a tetraphosphate.
  - 83. The process according to any of claim 63, 64, 65 or 67, wherein any of said nucleotide structures or nucleotide analog structures (i), (ii) or (iii) comprises nucleoside mono-, di- or tri-phosphate.
  - 84. The process according to claim 63, 64, 65 or 67, wherein SM comprises ribose, 2′
    - -deoxyribose, 3′
      
      -deoxyribose or 2′
      
      ,3′
      
      -dideoxyribose.
  - 85. The process according to any of claim 63, 64, 65 or 67, wherein BASE in any of said nucleotide structures or nucleotide analog structures (i), (ii) or (iii) comprises a 7-deazapurine.
  - 86. The process according to any of claim 63, 64, 65 or 67, wherein Sig in said nucleotide structure or nucleotide analog structure (i) is covalently attached to BASE the C2 position, the N3 position, the C6 position, or combinations thereof when BASE is a pyrimidine, or is covalently attached to BASE the N1 position, the C2 position, the N3 position, the C6 position, the N7 position, or combinations thereof when BASE is a purine.
  - 87. The process according to any of claim 63, 64, 65 or 67, wherein Sig in said nucleotide structure or nucleotide analog structure (i) is covalently attached to BASE at a position comprising the N⁴position when said pyrimidine comprises cytosine, the N²position when said purine comprises adenine or deazaadenine, the N⁶position when said purine comprises guanine or deazaguanine, or combinations thereof.
  - 88. The process according to claim 63, 64, 65 or 67, wherein in said nucleotide structure or nucleotide analog structure (ii), PM is attached to SM at the 2′
    - , 3′
      
      , 5′
      
      positions, or any combination thereof, and BASE is attached to the 1′
      
      position of SM from the N1 position when BASE is a pyrimidine or the N9 position when BASE is a purine or 7-deazapurine, and Sig is covalently attached to SM directly or through a linkage group and such covalent attachment does not substantially interfere with double helix formation or nucleic acid hybridization.
  - 89. The process according to claim 63, 64, 65 or 67, wherein in said nucleotide structure or nucleotide analog structure (iii), PM is attached to SM at the 2′
    - , 3′
      
      , 5′
      
      positions, or any combination thereof, and BASE is attached to the 1′
      
      position of SM from the N1 position when BASE is a pyrimidine or the N9 position when BASE is a purine or 7-deazapurine, and Sig is covalently attached to PM directly or through a linkage group and such covalent attachment does not substantially interfere with double helix formation or nucleic acid hybridization.
  - 90. The process according to any of claim 63, 64, 65 or 67, wherein said covalent attachment in nucleotide or nucleotide analog structure (iii) comprises
  - 91. The process according to any of claim 63, 64, 65 or 67, wherein PM comprises a mono-, di or tri-phosphate, and wherein in said nucleotide structure or nucleotide analog structure (iii), Sig is covalently attached to PM through a phosphorus or phosphate oxygen.
  - 92. The process according to any of claim 63, 64, 65 or 67, wherein said covalent attachment in any of said nucleotide structures or nucleotide analog structures (i), (ii) or (iii) does not interfere substantially with the characteristic ability of Sig to form a detectable non-radioactive signal.
  - 93. The process according to any of claim 63, 64, 65 or 67, wherein in any of said nucleotide structures or nucleotide analog structures (i), (ii) or (iii) said Sig is covalently attached to BASE, SM or PM through a linkage group.
  - 94. The process according to claim 93, wherein, in nucleotide structure or nucleotide analog structure (i), said linkage group contains an amine.
  - 95. The process according to claim 93, wherein said linkage group does not substantially interfere with formation of the signalling moiety or detection of the detectable non-radioactive signal.
  - 96. The process according to claim 94, wherein said amine comprises a primary amine.
  - 97. The process according to any of claim 63, 64, 65 or 67, wherein Sig comprises at least three carbon atoms.
  - 98. The process according to any of claim 63, 64, 65 or 67, wherein said Sig detectable non-radioactive moiety comprises an aliphatic chemical moiety comprising at least three carbon atoms and at least one double bond.
  - 99. The process according to any of claim 63, 64, 65 or 67, wherein said Sig detectable non-radioactive moiety comprises an aliphatic chemical moiety comprising at least four carbon atoms.
  - 100. The process according to any of claim 63, 64, 65 or 67, wherein said Sig detectable non-radioactive moiety comprises an aromatic or cycloaliphatic group comprising at least five carbon atoms.
  - 101. The process according to claim 100, wherein said aromatic or cycloaliphatic moiety is fluorescent or chemiluminescent.
  - 102. The process according to any of claim 63, 64, 65 or 67, wherein said Sig detectable non-radioactive moiety comprises an aromatic or cycloaliphatic group comprising at least six carbon atoms.
  - 103. The process according to claim 102, wherein said aromatic or cycloaliphatic moiety is fluorescent or chemiluminescent.
  - 104. The process according to any of claim 63, 64, 65 or 67, wherein Sig comprises a monosaccharide, polysaccharide or an oligosaccharide.
  - 105. The process according to any of claim 63, 64, 65 or 67, wherein Sig comprises biotin, iminobiotin, an electron dense component, a magnetic component, an enzyme, a hormone component, a metal-containing component, a fluorescent component, a chemiluminescent component, an antigen, a hapten, an antibody component, a chelating component, or any combination of any of the foregoing.
  - 106. The process according to claim 105, wherein said electron dense component comprises ferritin.
  - 107. The process according to claim 105, wherein said magnetic component comprises magnetic oxide or magnetic iron oxide.
  - 108. The process according to claim 105, wherein said magnetic component comprises magnetic beads.
  - 109. The process according to claim 105, wherein said enzyme comprises alkaline phosphatase, acid phosphatase, galactosidase, ribonuclease, glucose oxidase and peroxidase, or a combination thereof.
  - 110. The process according to claim 105, wherein said metal-containing component is catalytic.
  - 111. The process according to claim 105, wherein Sig comprises a fluorescent component.
  - 112. The process according to claim 105, wherein said fluorescent component comprises fluorescein, rhodamine or dansyl.
  - 113. The process according to claim 112, wherein said fluorescent component comprises fluorescein.
  - 114. The process according to claim 105, wherein Sig comprises an antigenic or hapten component capable of completing with an antibody specific to the component.
  - 115. The process according to any of claim 63, 64, 65 or 67, wherein Sig comprises a sugar residue and the sugar residue is complexed with or attached to a sugar binding protein or a polysaccharide binding protein.
  - 116. The process according to claim 115, wherein the binding protein comprises a lectin.
  - 117. The process according to claim 116, wherein the lectin comprises concanavalin A.
  - 118. The process according to claim 116, wherein said lectin is conjugated to ferritin.
  - 119. The process according to any of claim 63, 64, 65 or 67, wherein Sig is a non-radioactively detectable indicator molecule.
  - 120. The process according to claim 119, wherein said indicator molecule comprises an aromatic structure.
  - 121. The process according to claim 120, wherein said aromatic structure is heterocyclic.
  - 122. The process according to claim 121, wherein said heterocyclic aromatic structure is fluorescent.
  - 123. The process according to claim 122, wherein the fluorescent heterocyclic aromatic structure comprises fluorescein, rhodamine, dansyl, or a combination of any of the foregoing.
  - 124. The process according to claim 123, wherein said fluorescent heterocyclic aromatic structure comprises fluorescein.
  - 125. The process according to any of claim 63, 64, 65 or 67, wherein said Sig detectable non-radioactive moiety is a non-radioactively detectable indicator molecule.
  - 126. The process according to claim 125, wherein said indicator molecule comprises a fluorescent component, a chemiluminescent component, a chelating component, or a combination of any of the foregoing.
  - 127. The process according to any of claim 63, 64, 65 or 67, wherein any of said nucleotide structures or nucleotide analog structures (i), (ii) and (iii) are detectable by a means comprising a fluorescent measurement, a chemiluminescent measurement, or a combination thereof.
  - 128. The process according to any of claim 63, 64, 65 or 67, wherein Sig is detectable when the oligo- or polynucleotide is contained in a double-stranded ribonucleic or deoxyribonucleic acid duplex.
  - 129. The process according to any of claim 63, 64, 65 or 67, wherein Sig is detectable when it is attached to the nucleotide directly or through a linkage group.
  - 130. The process according to claim 129, wherein said linkage group does not interfere substantially with the characteristic ability of Sig to form a detectable signal.
  - 131. The process according to any of claim 63, 64, 65 or 67, wherein Sig in said nucleotide structure or nucleotide analog structure (iii) is covalently attached to PM via the chemical linkage
  - 132. The process according to any of claim 63, 64, 65 or 67, wherein Sig in said nucleotide structure or nucleotide analog structure (iii) is covalently attached to PM via a chemical linkage.
  - 133. The process according to any of claim 63, 64, 65 or 67, wherein the oligo- or polynucleotide is terminally ligated or attached to a polypeptide.
  - 134. The process according to claim 133, wherein the polypeptide comprises a polylysine.
  - 135. The process according to claim 133, wherein the polypeptide comprises avidin, streptavidin or anti-Sig immunoglobulin.
  - 136. The process according to any of claim 63, 64, 65 or 67, further comprising contacting the sample with a polypeptide capable of forming a complex with Sig and a moiety which can be detected when the complex is formed.
  - 137. The process according to claim 136, wherein the polypeptide comprises a polylysine.
  - 138. The process according to claim 136, wherein the polypeptide comprises avidin, streptavidin or anti-Sig immunoglobulin.
  - 139. The process according to claim 136, wherein Sig comprises a ligand and the polypeptide comprises an antibody thereto.
  - 140. The process according to claim 136, wherein the moiety which can be detected when the complex is formed comprises biotin, iminobiotin, an electron dense component, a magnetic component, an enzyme, a hormone component, a metal-containing component, a fluorescent component, a chemiluminescent component, an antigen, a hapten, an antibody component, a chelating component, or any combination of any of the foregoing.
  - 141. The process according to any of claim 63, 64, 65 or 67, wherein said detecting step is carried out directly.
  - 142. The process according to claim 141, wherein said direct detection is carried out on one or more non-radioactively detectable indicator molecules.
  - 143. The process according to claim 142, wherein said non-radioactively detectable indicator molecules comprise fluorescently labeled nucleotides.
  - 144. The process according to claim 143, wherein said fluorescently labeled nucleotides comprise fluorescent DNA.
  - 145. The process according to any of claim 63, 64, 65 or 67, wherein said detecting step is carried out by means of a directly detectable signal provided by said Sig detectable non-radioactive moiety.
  - 146. The process according to claim 145, wherein said detecting step is carried out by a fluorogenic structure, a chemiluminescent structure or an electron dense structure.
  - 147. The process according to claim 145, wherein said detecting step the directly detectable non-radioactive signal is provided by an enzyme.
  - 148. The process according to any of claim 63, 64, 65 or 67, wherein said detecting step is carried out by means of a indirectly detectable signal provided by said Sig detectable non-radioactive moiety.
  - 149. The process according to claim 148, wherein said detecting step the indirectly detectable non-radioactive signal is provided by an antibody, an antigen, a hapten, a receptor, a ligand or an enzyme.
  - 150. The process according to any of claim 63, 64, 65 or 67, wherein said Sig detectable non-radioactive moiety is capable of being detected by an enzymatic measurement, a fluorescent measurement, a chemiluminescent measurement, a microscopic measurement or an electron density measurement.
  - 151. The process according to any of claim 63, 64, 65 or 67, further comprising one or more washing steps.
  - 152. The process according to claim 63, 64, 65 or 67, wherein said one or more clones or DNA fragments or oligo- or polynucleotides derived from clone or clones are derived from said particular chromosome or said chromosome of interest or said chromosome in said interphase cell of interest.
  - 153. The process according to any of claims 63, 64 or 65, wherein said detecting step is carried out by a means comprising manual means or automatic means.
  - 154. The process according to claim 153, wherein said manual means comprises visualization.
  - 155. The process according to claim 153, wherein said automatic means comprises computerized automatic karyotyping.
  - 181. The process of any of claim 40, 42, 101, or 103, wherein said fluorescent aromatic or cycloaliphatic group comprises a fluorescent dye.

64. A process for identifying a chromosome of interest in a cell containing other chromosomes, the process comprising:
- providing at least one cell;
  
  providing a set of clones or DNA fragments, or oligo- or polynucleotides derived from said clone or clones, wherein said clones or fragments or oligo- or polynucleotides are specifically hybridizable to a locus or loci in said chromosome of interest, wherein said clones or fragments or said oligo- or polynucleotides comprise one or more detectable non-radioactive modified or labeled nucleotides or one or more detectable non-radioactively modified or labeled nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and wherein said modified or labeled nucleotides or modified or labeled nucleotide analogs comprise;
  
  (i) a nucleotide structure or nucleotide analog structure having the formula
  PM-SM-BASE-SigwhereinPM is a phosphate moiety,SM is a furanosyl moiety,BASE is a pyrimidine, a purine, or a 7-deazapurine base moiety, andSig is a detectable non-radioactive moiety, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE at a position other than the C5 position when BASE is a pyrimidine moiety, at a position other than the C8 position when BASE is a purine moiety, and at a position other than the C7 position when BASE is a 7-deazapurine moiety;
  
  (ii) a nucleotide structure or nucleotide analog structure having the formula

65. A process for identifying a plurality or all of the chromosomes in a cell of interest, the process comprising:
- providing at least one cell;
  
  providing sets of clones or DNA fragments, or oligo- or polynucleotides derived from said clones, wherein said clones or fragments or said oligo- or polynucleotides are capable of hybridizing specifically to a locus or loci in a chromosome of said cell of interest, wherein each of said clones or DNA fragments or oligo- or polynucleotides in said sets are labeled with a different indicator moiety and each of said clones or DNA fragments or oligo- or polynucleotides comprises one or more detectable non-radioactive modified or labeled nucleotides or one or more detectable non-radioactive modified or labeled nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and wherein said modified or labeled nucleotides or modified or labeled nucleotide analogs comprise;
  
  (i) a nucleotide structure or nucleotide analog structure having the formula
  PM-SM-BASE-SigwhereinPM is a phosphate moiety,SM is a furanosyl moiety,BASE is a pyrimidine, a purine, or a 7-deazapurine base moiety, andSig is a detectable non-radioactive moiety,wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE at a position other than the C5 position when BASE is a pyrimidine, at a position other than the C8 position when BASE is a purine, and at a position other than the C7 position when BASE is a 7-deazapurine;
  
  (ii) a nucleotide structure or nucleotide analog structure having the formula
- View Dependent Claims (66)
- - 66. The process according to claim 65, wherein each of said set of clones or DNA fragments or oligo- or polynucleotides is labeled with the same indicator molecule.

67. A process for determining the number of chromosomes in an interphase cell of interest, the process comprising:
- providing at least one interphase cell;
  
  providing sets of clones or DNA fragments or oligo- or polynucleotides derived from said clones, wherein said set of clones or DNA fragments or oligo- or polynucleotides are specifically complementary to or specifically hybridizable with at least one locus or loci in a chromosome of said interphase cell of interest and each of said clones or DNA fragments or oligo- or polynucleotides in said sets comprises one or more detectable non-radioactive modified or labeled nucleotides or detectable non-radioactively modified or labeled nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and wherein said modified or labeled nucleotides or modified or labeled nucleotide analogs comprise one or more of;
  
  (i) a nucleotide structure or nucleotide analog structure having the formula
  PM-SM-BASE-SigwhereinPM is a phosphate moiety,SM is a furanosyl moiety,BASE is a pyrimidine, a purine, or a 7-deazapurine base moiety, andSig is a detectable non-radioactive moiety,wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE at a position other than the C5 position when BASE is a pyrimidine moiety, at a position other than the C8 position when BASE is a purine, and at a position other than the C7 position when BASE is a 7-deazapurine;
  
  (ii) a nucleotide structure or nucleotide analog structure having the formula
- View Dependent Claims (68, 69, 70, 71, 72)
- - 68. The process according to claim 67, wherein each of said sets of clones or DNA fragments or oligo- or polynucleotides is labeled with the same indicator molecule.
  - 69. The process according to claim 67, wherein each of said sets of clones or DNA fragments or oligo- or polynucleotides is labeled with a different indicator molecule.
  - 70. The process according to claim 67, wherein said detecting and determining step is carried out by a means comprising manual means or automatic means.
  - 71. The process according to claim 70, wherein said manual means comprises visualization.
  - 72. The process according to claim 70, wherein said automatic means comprises computerized automatic karyotyping.

156. A process for detecting a nucleic acid of interest in a sample, which process comprises:
- (a) providing a sample which may comprise a nucleic acid of interest;
  
  (b) providing a metal or metal ion;
  
  (c) specifically hybridizing said nucleic acid of interest in the sample with one or more oligo- or polynucleotides, each such oligo- or polynucleotide being complementary to or capable of hybridizing with said nucleic acid of interest or a portion thereof, wherein said oligo- or polynucleotides comprise one or more detectable non-radioactive modified or labeled nucleotides or detectable non-radioactive modified or labeled nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and wherein said modified or labeled nucleotides or modified or labeled nucleotide analogs comprise a nucleotide structure or nucleotide analog structure comprising;
  
  (i) a nucleotide structure or nucleotide analog structure having the formula
  PM-SM-BASE-SigwhereinPM is a phosphate moiety,SM is a furanosyl moiety,BASE is a pyrimidine, a purine or a 7-deazapurine base moiety; and
  
  Sig is a signalling moiety comprising a chelating structure or component capable of chelating said metal or metal ion and providing a detectable signal, wherein Sig comprises at least three carbon atoms, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE directly or through a linkage group at a position other than the C5 position when BASE is a pyrimidine moiety, at a position other than the C8 position when BASE is a purine moiety and at a position other than the C7 position when BASE is a 7-deazapurine moiety, and such covalent attachment does not substantially interfere with double helix formation or nucleic acid hybridization;
  
  (ii) a nucleotide structure or nucleotide analog structure having the formula
- View Dependent Claims (157, 174, 175, 176, 177, 178, 179, 180, 182, 183, 184, 185, 186, 187)
- - 157. The process of claim 156, wherein in said specific hybridizing step, the chelating structure or chelating components provide a detectable signal that is radioactive, fluorogenic, fluorescent, chemiluminescent, electron dense or magnetic.
  - 174. The process of any of claim 156, 158, 159, 161, 162 or 163, wherein said detecting step is carried out by a structure or component that is radioactive, fluorogenic, fluorescent, chemiluminescent, electron dense or magnetic.
  - 175. The process of claim 174, wherein said detecting step is carried out radioactively.
  - 176. The process of claim 175, wherein said radioactive detection is carried out by means of an isotope.
  - 177. The process of claim 175, wherein said radioactive detection is carried out with an isotope comprising bismuth-206, bismuth-207, cobalt-60, gadolinium-153, strontium-90 or yttrium-90.
  - 178. The process of claim 176, wherein said isotope is a β
    - or γ
      
      emitter.
  - 179. The process of any of claim 156, 158, 159, 161, 162, or 163, wherein in said detecting step, the chelating structure or chelating components have a chelated metal or metal ion comprising heavy metals or rare earth metals.
  - 180. The process of claim 179, wherein said heavy metal comprises cobalt.
  - 182. The process of any of claim 63, 64, 65, 67, 156, 159, 161, 162, 163, or 164, wherein said base comprises a pyrimidine analog or a purine analog.
  - 183. The process of claim 182, wherein said pyrimidine analogs comprise thymidine analogs, uridine analogs, deoxyuridine analogs, cytidine analogs or deoxycytidine analogs.
  - 184. The process of claim 183, wherein said uridine analogs comprise 5-bromo-2′
    - -deoxyuridine-5′
      
      -phosphate.
  - 185. The process of claim 183, wherein said deoxycytidine analogs comprise 5-hydroxymethyl-2′
    - -deoxycytidylic acid.
  - 186. The process of claim 182, wherein said purine analog comprises adenosine analogs, deoxyadenosine analogs, guanosine analogs or deoxyguanosine analogs.
  - 187. The process of claim 186, wherein said adenosine analogs comprise tubericidin or toyocamycin.

158. A process for detecting a nucleic acid of interest in a sample, which process comprises:
- (A) providing;
  
  (i) an oligo- or polynucleotide having two segments;
  
  (a) a first segment complementary to and capable of hybridizing to a portion of said nucleic acid of interest; and
  
  (b) a second segment comprising at least one protein binding sequence; and
  
  (ii) a metal or metal ion;
  
  (iii) a detectable protein capable of binding to said protein binding sequence and comprising a chelating structure or chelating component capable of chelating said metal or metal ion and providing a detectable signal;
  
  (B) contacting a sample suspected of containing said nucleic acid of interest with said oligo- or polynucleotide and said detectable protein (ii) to form a complex;
  
  (C) detecting the presence of said protein in said complex and said nucleic acid of interest by means of said metal or metal ion chelated by said chelating structure or chelating component.
- View Dependent Claims (173)
- - 173. The process of any of claim 158, 161, 162, 163 or 164, wherein in said providing step, the chelating structure or chelating components provide a detectable signal that is radioactive, fluorogenic, fluorescent, chemiluminescent, electron dense or magnetic.

159. A process for determining whether the number of copies of a particular chromosome in a cell is normal or abnormal, the process comprising:
- providing a cell;
  
  providing a metal or metal ion;
  
  contacting said cell under hybridizing conditions with one or more clones or DNA fragments, or oligo- or polynucleotides derived from said clone or clones, wherein said clones or fragments or oligo- or polynucleotides are capable of hybridizing specifically to a locus or loci of said particular chromosome or a portion thereof, wherein said clones or fragments or oligo- or polynucleotides comprise one or more detectable non-radioactive modified or labeled nucleotides or detectable non-radioactive modified or labeled nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and wherein said modified or labeled nucleotides or modified or labeled nucleotide analogs comprise a nucleotide structure or nucleotide analog structure comprising;
  
  (i) a nucleotide structure or nucleotide analog structure having the formula
  PM-SM-BASE-SigwhereinPM is a phosphate moiety,SM is a furanosyl moiety,BASE is a pyrimidine, a purine, or a 7-deazapurine base moiety, andSig is a signalling moiety comprising a chelating structure or chelating component capable of chelating said metal or metal ion and providing a detectable signal, wherein PM is covalently attached to the SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE at a position other than the C5 position when BASE is a pyrimidine moiety, at a position other than the C8 position when BASE is a purine moiety, and at a position other than the C7 position when BASE is a 7-deazapurine moiety;
  
  (ii) a nucleotide structure or nucleotide analog structure having the formula
- View Dependent Claims (160)
- - 160. The process of claim 159, wherein in said contacting step, the chelating structure or chelating components provide a detectable signal that is radioactive, fluorogenic, fluorescent, chemiluminescent, electron dense or magnetic.

161. A process for identifying a chromosome of interest in a cell containing other chromosomes, the process comprising:
- providing a cell;
  
  providing a metal or metal ion;
  
  providing a set of clones or DNA fragments, or oligo- or polynucleotides derived from said clone or clones, wherein said clones or fragments or oligo- or polynucleotides are specifically hybridizable to a locus or loci in said chromosome of interest, wherein said clones or fragments or oligo- or polynucleotides comprise one or more detectable modified or labeled nucleotides or detectable modified or labeled nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and wherein said modified or labeled nucleotides or modified or labeled nucleotide analogs comprise a nucleotide structure or nucleotide analog structure comprising;
  
  (i) a nucleotide structure or nucleotide analog structure having the formula
  PM-SM-BASE-SigwhereinPM is a phosphate moiety,SM is a furanosyl moiety,BASE is a pyrimidine, a purine, or a 7-deazapurine base moiety, andSig is a signalling moiety comprising a chelating structure or chelating component capable of chelating said metal or metal ion and providing a detectable signal, wherein Sig comprises at least three carbon atoms, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE at a position other than the C5 position when BASE is a pyrimidine moiety, at a position other than the C8 position when BASE is a purine moiety, and at a position other than the C7 position when BASE is a 7-deazapurine moiety;
  
  (ii) a nucleotide structure or nucleotide analog structure having the formula

162. A process for identifying a plurality or all of the chromosomes in a cell of interest, the process comprising:
- providing a cell of interest;
  
  providing a metal or metal ion;
  
  providing sets of clones or DNA fragments, or oligo- or polynucleotides derived from said clones, wherein each of said set of clones or DNA fragments or oligo- or polynucleotides are specifically hybridizable to a locus or loci in a chromosome of said cell of interest, wherein each of said clones or DNA fragments or oligo- or polynucleotides comprise one or more detectable modified or labeled nucleotides or detectable modified or labeled nucleotide analogs capable of detection, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA and wherein each set comprises a different indicator molecule, and wherein said modified or labeled nucleotide or modified or labeled nucleotide analogs comprise a nucleotide structure or nucleotide analog structure comprising;
  
  (i) a nucleotide structure or nucleotide analog structure having the formula
  PM-SM-BASE-SigwhereinPM is a phosphate moiety,SM is a furanosyl moiety,BASE is a pyrimidine, a purine, or a 7-deazapurine base moiety, andSig is a signalling moiety comprising a chelating structure or chelating component capable of chelating said metal or metal ion and providing a detectable signal, wherein Sig comprises at least three carbon atoms, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE at a position other than the C5 position when BASE is a pyrimidine, at a position other than the C8 position when BASE is a purine, and at a position other than the C7 position when BASE is a 7-deazapurine;
  
  (ii) a nucleotide structure or nucleotide analog structure having the formula

163. A process for determining the number of chromosomes in an interphase cell of interest, the process comprising:
- providing an interphase cell of interest;
  
  providing a metal or metal ion;
  
  providing sets of clones or DNA fragments, or oligo- or polynucleotides derived from said clones, wherein each of said set of clones or DNA fragments or oligo- or polynucleotides are specifically complementary to or specifically hybridizable with at least one locus or loci in a chromosome of said interphase cell of interest, wherein each of said clones or DNA fragments or oligo- or polynucleotides in said sets comprise one or more detectable modified or labeled nucleotides or detectable modified or labeled nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and wherein said modified or labeled nucleotide or modified or labeled nucleotide analog comprise a nucleotide structure or nucleotide analog structure comprising;
  
  (i) a nucleotide structure or nucleotide analog structure having the formula
  PM-SM-BASE-SigwhereinPM is a phosphate moiety,SM is a furanosyl moiety,BASE is a pyrimidine, a purine, or a 7-deazapurine base moiety, andSig is a signalling moiety comprising a chelating structure or chelating component capable of chelating said metal or metal ion and providing a detectable signal, wherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE at a position other than the C5 position when BASE is a, pyrimidine moiety, at a position other than the C8 position when BASE is a purine, and at a position other than the C7 position when BASE is a 7-deazapurine;
  
  (ii) a nucleotide structure or nucleotide analog structure having the formula

164. A process for preparing a labeled oligo- or polynucleotide of interest, comprising:
- (A) providing a metal or metal ion;
  
  (B) providing;
  
  (1) one or more detectable chemically modified or labeled nucleotides or detectable chemically modified or labeled nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA or an oligo- or polynucleotide of interest, alone or in conjunction with one or more other modified or unmodified nucleic acids selected from the group consisting of nucleotides, oligonucleotides and polynucleotides, wherein said other modified or unmodified nucleic acids are capable of incorporating into an oligo- or polynucleotide of interest, and wherein said modified or labeled nucleotides or nucleotide analogs comprise one or more signalling moieties comprising a chelating structure or chelating component capable of chelating a metal or metal ion and providing a detectable signal,(2) an oligo- or polynucleotide comprising one or more of said modified or labeled nucleotides or modified or labeled nucleotide analogs (1), alone or in conjunction with one or more other modified or unmodified nucleic acids selected from the group consisting of nucleotides, oligonucleotides and polynucleotides, or(3) both (1) and (2),wherein said modified or labeled nucleotides or modified or labeled nucleotide analogs (1) are modified on the furanosyl moiety, the phosphate moiety, the base moiety or any combination thereof, and wherein the modified or labeled nucleotides or modified or labeled nucleotide analogs comprise a nucleotide structure or nucleotide analog structure comprising;
  
  PM-SM-BASE-Sig
  
  (i)whereinPM is a phosphate moiety,SM is a furanosyl moiety,BASE is a pyrimidine, a purine or a 7-deazapurine base moiety, andSig is a signalling moiety comprising a chelating structure or chelating component capable of chelating said metal or metal ion and providing a detectable signal, wherein Sig comprises at least three carbon atoms, andwherein PM is covalently attached to SM, BASE is covalently attached to SM, and Sig is covalently attached to BASE directly or through a linkage group at a position other than the C5 position when BASE is a pyrimidine moiety, at a position other than the C8 position when BASE is a purine moiety, and at a position other than the C7 position when BASE is a 7-deazapurine moiety;
  
  (ii)

165. A process for detecting the presence of a nucleic acid of interest in a sample, comprising:
- providing a sample which may contain a nucleic acid of interest;
  
  providing or generating (i) one or more detectable non-radioactively labeled oligonucleotides or polynucleotides, each of said detectable non-radioactively labeled oligonucleotides or polynucleotides comprising a sequence sufficiently complementary to said nucleic acid of interest or to a portion thereof to specifically hybridize therewith, wherein said detectable non-radioactively labeled oligonucleotides or polynucleotides comprise one or more detectable non-radioactively modified or labeled nucleotides or detectable non-radioactively modified or labeled nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and (ii) a sample that may contain said nucleic acid of interest;
  
  forming in liquid phase hybrids comprising said detectable non-radioactively labeled oligonucleotides or polynucleotides specifically hybridized with said nucleic acid of interest;
  
  separating or resolving in a gel said formed hybrids; and
  
  detecting non-radioactively the separated or resolved hybrids to detect the presence of said nucleic acid of interest.
- View Dependent Claims (166, 167, 168, 169, 170, 171, 172)
- - 166. The process according to claim 165, further comprising after said hybrid forming step, the step of subjecting the liquid phase to nuclease treatment.
  - 167. The process according to claim 165, wherein said nucleic acid of interest comprises DNA, RNA or DNA-RNA.
  - 168. The process according to claim 165, wherein said one or more detectable oligonucleotides or polynucleotides comprises DNA, RNA or DNA-RNA.
  - 169. The process according to claim 165, wherein said one or more detectable oligonucleotides or polynucleotides comprise biotin, iminobiotin, an electron dense component, a magnetic component, an enzyme, a hormone component, a metal-containing component, a fluorescent component, a chemiluminescent component, an antigen, a hapten, an antibody component, a chelating component or a combination of any of the foregoing.
  - 170. The process according to claim 165, wherein said non-radioactive detection step is carried out directly or indirectly.
  - 171. The process according to claim 165, wherein said detecting step is carried out by means of an enzymatic measurement, a fluorescent measurement, a chemiluminescent measurement, a microscopic measurement or an electron density measurement.
  - 172. The process according to claim 165, wherein said detecting step comprises localizing said separated or resolved hybrids.

188. A process for detecting the presence of a nucleic acid of interest in a sample, comprising:
- providing or generating (i) one or more detectable non-radioactively labeled oligonucleotide or polynucleotide, each of said detectable non-radioactively labeled oligonucleotide or polynucleotide comprising a sequence sufficiently complementary to said nucleic acid of interest or to a portion thereof to specifically hybridize therewith, wherein said detectable non-radioactively labeled oligonucleotides or polynucleotides comprise one or more detectable non-radioactively modified or labeled nucleotides or detectable non-radioactively modified or labeled nucleotide analogs, which nucleotide analogs can be attached to, coupled to, or incorporated into DNA or RNA, and (ii) a sample that may contain said nucleic acid of interest;
  
  forming liquid phase hybrids comprising said detectable non-radioactively labeled oligonucleotides or polynucleotides specifically hybridized with said nucleic acid of interest;
  
  subjecting said liquid phase to nuclease treatment to digest non-hybridized single-stranded detectable non-radioactively labeled oligonucleotides or polynucleotides and leave said hybrids intact; and
  
  detecting the hybrids non-radioactively to detect the presence of said nucleic acid of interest.
- View Dependent Claims (192, 193, 194, 195, 196, 197, 198)
- - 192. The process according to claim 188 or 191 wherein said nuclease treatment is carried out by S1 nuclease, Exonuclease I from E. coli, or a combination thereof.
  - 193. The process according to any of claim 188, 189, 190 or 191 further comprising separating or resolving in a gel said formed hybrids.
  - 194. The process according to claim 188 or 189, wherein said nucleic acid of interest comprises DNA, RNA or DNA-RNA.
  - 195. The process according to claim 188 or 189, wherein said detectable oligonucleotide or polynucleotide comprises DNA, RNA or DNA-RNA.
  - 196. The process according to claim 188 or 189, wherein said detectable oligonucleotide or polynucleotide comprises biotin, iminobiotin, an electron dense component, a magnetic component, an enzyme, a hormone component, a metal-containing component, a fluorescent component, a chemiluminescent component, an antigen, a hapten, an antibody component, a chelating component or a combination of any of the foregoing.
  - 197. The process according to claim 188 or 189, wherein said non-radioactive detection step is carried out directly or indirectly.
  - 198. The process according to claim 188 or 189, wherein said detecting step is carried out by means of an enzymatic measurement, a fluorescent measurement, a chemiluminescent measurement, a microscopic measurement or an electron density measurement.

189. A process for detecting the presence of a nucleic acid of interest in a sample, comprising:
- providing or generating (i) a detectable non-radioactively labeled oligonucleotide or polynucleotide, said detectable non-radioactively labeled oligonucleotide or polynucleotide comprising a sequence sufficiently complementary to said nucleic acid of interest or to a portion thereof to specifically hybridize therewith, wherein said detectable non-radioactively labeled oligonucleotide or polynucleotide comprises one or more detectable non-radioactively modified or labeled nucleotides or detectable non-radioactively modified or labeled nucleotide analogs, which nucleotide analogs can be attached to or coupled to or incorporated into DNA or RNA, and (ii) a sample that may contain said nucleic acid of interest;
  
  forming in liquid phase, hybrids comprising said detectable non-radioactively labeled oligonucleotide or polynucleotide specifically hybridized with said nucleic acid of interest; and
  
  detecting hybrids non-radioactively to detect the presence of said nucleic acid of interest.
- View Dependent Claims (190, 191)
- - 190. The process according to claim 189, further comprising a treatment that acts upon a non-hybridized detectable non-radioactiviely labeled oligonucleotide or polynucleotide and leaves a hybridized detectable non-radioactively labeled oligonucleotide or polynucleotide intact.
  - 191. The process according to claim 190 wherein said treatment is a nuclease treatment.

Specification

Resources

Litigation Campaign Assessment

Litigation Data

Current Assignee
Enzo Life Sciences Incorporated (Enzo Biochem Incorporated)
Original Assignee
Enzo Biochem Incorporated
Inventors
Engelhardt, Dean, Rabbani, Elazar, Kline, Stanley, Stavrianopoulos, Jannis G., Kirtikar, Dollie
Primary Examiner(s)
Brusca, John S

Application Number

US08/486,069
Time in Patent Office

6,068 Days
Field of Search

435/5, 435/6, 435/7.1, 435/91.1, 435/91.2, 435/810, 436/501, 436/63, 536/22.1, 536/23.1, 536/24.1, 536 243- 2433, 536/25.3, 735/77, 735/78
US Class Current

435/6
CPC Class Codes

A61K 47/62   the modifying agent being a...

C07B 59/008   Peptides; Proteins

C07H 19/04   Heterocyclic radicals conta...

C07H 19/10   with the saccharide radical...

C07K 17/06   attached to the carrier via...

C12Q 1/6804   Nucleic acid analysis using...

C12Q 1/6816   characterised by the detect...

C12Q 2525/117   incorporating modified base

Nucleic acid sequencing processes using non-radioactive detectable modified or labeled nucleotides or nucleotide analogs, and other processes for nucleic acid detection and chromosomal characterization using such non-radioactive detectable modified or labeled nucleotides or nucleotide analogs

First Claim

1 Assignment

Litigations

0 Petitions

Accused Products

Abstract

75 Citations

198 Claims

Specification

Use Cases

Quick Links

Others

Nucleic acid sequencing processes using non-radioactive detectable modified or labeled nucleotides or nucleotide analogs, and other processes for nucleic acid detection and chromosomal characterization using such non-radioactive detectable modified or labeled nucleotides or nucleotide analogs

First Claim

1 Assignment

Subscription Required

Subscription Required

Litigations

0 Petitions

Subscription Required

Accused Products

Subscription Required

Abstract

75 Citations

198 Claims

Specification

Subscription Required

Use Cases

Quick Links

Others